We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+23.8%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$376M
AUM Growth
+$23.8M
Cap. Flow
-$13.2M
Cap. Flow %
-3.51%
Top 10 Hldgs %
36.6%
Holding
101
New
12
Increased
44
Reduced
25
Closed
20

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$9.17M
2
PCVX icon
Vaxcyte
PCVX
+$6.2M
3
UTHR icon
United Therapeutics
UTHR
+$4.65M
4
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$4.54M
5
BIIB icon
Biogen
BIIB
+$4.3M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$11.2M
2
WAT icon
Waters Corp
WAT
+$5.96M
3
RCM
R1 RCM Inc. Common Stock
RCM
+$5.16M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$4.24M
5
IQV icon
IQVIA
IQV
+$4.02M

Sector Composition

Rank Sector Weight
1 Healthcare 98.13%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMUX icon
76
Immunic
IMUX
$217M
$644K 0.17%
45,977
-19,787
-30% -$540K
TVTX icon
77
Travere Therapeutics
TVTX
$5.86B
$480K 0.13%
22,835
-3,730
-14% -$79K
EWTX icon
78
Edgewise Therapeutics
EWTX
$4.73B
$473K 0.13%
52,896
+2,896
+6% +$27.1K
CNSY
79
Cerenome, Inc. Common Stock
CNSY
$25.5M
$185K 0.05%
1,556
-1,977
-56% -$315K
UBX
80
DELISTED
Unity Biotechnology
UBX
$117K 0.03%
42,749
+2,340
+6% +$6.8K
AFIB
81
DELISTED
Acutus Medical Inc
AFIB
$59.8K 0.02%
+52,027
New +$42.9K
ALNY icon
82
Alnylam Pharmaceuticals
ALNY
$30B
– –
-10,873
Closed -$2.18M
BLRX
83
BioLineRX
BLRX
$11.7M
– –
-7,221
Closed -$267K
BMRN icon
84
BioMarin Pharmaceuticals
BMRN
$13.6B
– –
-42,961
Closed -$3.64M
CDXS icon
85
Codexis
CDXS
$172M
– –
-105,319
Closed -$638K
CVS icon
86
CVS Health
CVS
$121B
– –
-117,634
Closed -$11.2M
ESTA icon
87
Establishment Labs
ESTA
$2.25B
– –
-15,173
Closed -$829K
HBIO icon
88
Harvard Bioscience
HBIO
$27.8M
– –
-30,535
Closed -$782K
IRTC icon
89
iRhythm Holdings
IRTC
$4.13B
– –
-25,458
Closed -$3.19M
ISRG icon
90
Intuitive Surgical
ISRG
$142B
– –
-15,000
Closed -$2.81M
PEPG icon
91
PepGen
PEPG
$201M
– –
-100,000
Closed -$908K
STIM icon
92
Neuronetics
STIM
$223M
– –
-85,866
Closed -$273K
TMO icon
93
Thermo Fisher Scientific
TMO
$223B
– –
-7,500
Closed -$3.8M
VRDN icon
94
Viridian Therapeutics
VRDN
$2.59B
– –
-35,358
Closed -$725K
XAIR icon
95
Beyond Air
XAIR
$5.37M
– –
-316
Closed -$941K
CTLT
96
DELISTED
CATALENT, INC.
CTLT
– –
-45,304
Closed -$3.28M
RCM
97
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-278,486
Closed -$5.16M
SIEN
98
DELISTED
Sientra, Inc.
SIEN
– –
-37,359
Closed -$239K
NSTG
99
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-242,600
Closed -$3.1M
APEN
100
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-657,690
Closed -$3.62M
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Parkman Healthcare Partners held 101 positions worth $376M, up 6.8% from $352M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Parkman Healthcare Partners withdrew a net $13.2M in Q4 2022, closing 20 positions and reducing 25 holdings. Its most notable exit was CVS Health, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Humana worth $8.93M.

  • Parkman Healthcare Partners's largest Q4 2022 buy was Humana: 17,439 shares worth $8.93M.
  • Parkman Healthcare Partners added most to United Therapeutics in Q4 2022, an estimated $4.65M increase.
  • Parkman Healthcare Partners's biggest Q4 2022 reduction was Waters Corp, cutting an estimated $5.96M.
  • Parkman Healthcare Partners fully exited CVS Health in Q4 2022, selling an estimated $11.2M.
  • Parkman Healthcare Partners's ten largest holdings make up 37% of its $376M portfolio in Q4 2022.
  • Parkman Healthcare Partners opened 12 new positions and closed 20 in Q4 2022.
  • Parkman Healthcare Partners's portfolio value rose 6.8% quarter-over-quarter to $376M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2022, filed 13 Feb 2023.